Navigation Links
China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results

HARBIN, China, Nov. 17 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced record financial results for the third quarter of 2009.

    Third Quarter 2009 Highlights

    -- Total revenues increased 45.5% year-over-year to $43.2 million
    -- Gross profit increased 44.8% year-over-year to $32.3 million
    -- Operating income increased 27.8% to $16.1 million
    -- Net income increased 25.3% year-over-year to $12.5 million, or $0.74
       per diluted share
    -- Obtained renewal of GMP certificate for Peng Lai Jin Chuang
       Pharmaceutical Company subsidiary from the State Food and Drug
       Administration ("SFDA") valid through June 2014
    -- Appointed new independent director who serves as a member in the audit
    -- Submitted application to the SFDA to perform clinical trials for two
       new eye drugs
    -- Expanded international sales by exporting Pain Relief patches to Canada
    -- Held first Annual Meeting of Shareholders on September 24th 2009 in

"We are delighted to report another quarter of excellent results. We achieved record financial performance in the third quarter driven by strong product sales and the strength of our growing sales and distribution network. Sales of ointment and spray products increased as we promoted our skin-care products under the 'Yu Fu' brand. Sales of diversified products from our business acquisitions in 2008 also made a strong contribution to our third quarter results as we continued to execute our business strategy," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical.

Third Quarter 2009 Results

Total revenues increased 45.5% year-over-year to $43.2 million for the three months ended September 30, 2009. The increase was primarily attributable to the strong performance of the Company's larger sales team and great number of sales agents, as well as contributions from its business acquisitions in 2008.

Sales of patch products totaled $11.8 and accounted for 27.3% of revenue in the third quarter of 2009, versus $13.0 million and 43.6% of revenue for the same period last year due to a change in the Company's marketing strategy after the acquisition of Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company to focus on certain of their products. Sales of ointments rose 38.0% year-over-year to $10.8 million, accounting for 25.0% of revenue, versus $7.8 million, or 26.4% of revenue a year ago. Sales of spray products approximately doubled to $6.8 million and accounted for 15.6% of revenue, versus 10.7% a year ago. The increase in spray products was primarily due to increased sales of mouth sprays resulting from the outbreak of the H1N1 virus. Sales of bio-engineering products, which comprise the Company's three diagnostic testing kits, rose 8.5% year-over-year to $2.6 million, accounting for 6.1% of revenue. Sales of the Company's other 48 products reached $11.2 million for the third quarter of 2009, compared to $3.3 million for its other same products in the same period last year. The higher sales in this category were mainly due to an increase in diversified products from the acquisitions of Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company in 2008.

Gross profit in the third quarter of 2009 was $32.3 million, an increase of 44.8% over the same period a year ago. Gross margin was 74.8% in the third quarter, a slight decrease compared to gross margin of 75.2% for the third quarter of 2008.

Operating expenses in the third quarter of 2009 were $16.3 million, up 66.8% from $9.8 million in the third quarter of 2008. The increase was mainly the result of higher research and development expenses associated with ongoing clinical trials for proposed products, the development of patents, licenses and other technologies acquired in 2008, and higher selling, general and administrative expenses primarily attributable to increased selling and marketing costs used to support the Company's sales growth.

Operating income was $16.1 million for the third quarter of 2009, representing a 27.8% increase from $12.6 million in the third quarter of 2008. Operating margin was 37.1%, compared to 42.3% in the third quarter of 2008.

Provision for income taxes was $3.6 million in the third quarter of 2009, compared to $2.6 million in the same period last year.

Net income for the third quarter of 2009 was $12.5 million, or $0.74 per diluted share, compared to net income of $9.9 million, or $0.60 per diluted share, in the third quarter of 2008. Diluted earnings per share were calculated using a weighted average share count of 16.7 million in the third quarter of 2009, compared to 15.5 million a year ago.

Nine Month Operating Highlights

Total revenues for nine months ended September 30, 2009 increased 52.2% year-over-year to $100.2 million as a result of the Company's expanded distribution channels and successful acquisitions. Gross margin was about 75.4% compared to 76.1% for the first nine months of 2008. Net income for the first nine months of 2009 reached $29.2 million, or $1.76 per diluted share, compared to net income of $21.9 million, or $1.39 per diluted share, in the same period of 2008.

Financial Condition

As of September 30, 2009, China Sky One Medical had $56.3 million in cash and cash equivalents, or $3.38 per common share outstanding, approximately $79.1 million in working capital, and no debt. Stockholders' equity at September 30, 2009, was $124.4 million, a 31.1% increase over the $94.9 million recorded at December 31, 2008.

The Company generated $25.9 million in net cash flow from operating activities in the first nine months of 2009. As of September 30, 2009, the Company had spent approximately $9.9 million in constructing a new corporate headquarters in Harbin Song Bei New Development District. Construction is expected to be completed by the end of 2009. The estimated cost of this project is approximately $13 million. The Company is moving its administration offices and R&D laboratories to the new facility in November 2009. It is expected that this facility will also house a cord stem cell and tissue bank in the future. The Company believes that combining its operations into one centralized location will result in greater efficiency and will make it easier for management to conduct business activities. The company plans to fund the entire project using its internal funds.

Business Outlook and Guidance

"We are confident about the prospects for our business in 2009 and will continue to focus on increasing market share by both strengthening and further refining our sales and distribution network, building and enhancing our brand image, and seeking out strategic acquisitions that support our growth. In the first nine months of 2009, we increased our number of sales representatives to roughly 1,500 from 1,300. Currently, our products are sold in approximately 5,500 pharmacies in 24 provinces in China compared to 4,500 pharmacies in 22 provinces in 2008. Over the long term, we will continue to focus on developing and manufacturing our biological diagnostic kits and on our cord stem cell bank initiative, areas that we believe have very promising market opportunities," said Mr. Liu.

"Based on our progress so far this year, we are reaffirming our guidance for the year," added Mr. Liu. "We expect 2009 full year revenue to increase by 40%, or approximately $37.0 million, to $130 million, driven by growth in all of our product sales categories. We estimate that 2009 gross margin to be approximately 75%, which factors in market competition and possibly higher raw material costs. We expect 2009 net income will increase to approximately $39 million, resulting in net profit margin of approximately 30%."

Conference Call

The Company will conduct a conference call at 8:00 a.m. Eastern Standard Time on Tuesday, November 17, 2009, to discuss its third quarter of fiscal year 2009 financial results. Joining Mr. Liu will be Stanley Hao, Chief Financial Officer of China Sky One Medical Inc. To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 1 888 419 5570. International callers should dial +1 617 896 9871. The Conference ID for this call is 814 194 70. If you are unable to participate in the call at this time, a replay will be available for fourteen days starting on Tuesday, November 17, 2009 at 10:00 a.m. Eastern Time. To access the replay, dial 888 286 8010, international callers dial 617 801 6888 The Conference Replay Passcode is 254 153 02.

About China Sky One Medical, Inc.

China Sky One Medical, Inc. is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company the Company manufactures and distributes over-the- counter pharmaceutical products, which make up its major revenue source. For more information, visit .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development and market conditions. Actual results could differ materially from the expectations reflected in such forward- looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

                          Financial Statements Below

                China Sky One Medical, Inc. and Subsidiaries
                    Condensed Consolidated Balance Sheets

                                        September 30,       December 31,
                                             2009               2008
                                         (Unaudited)          (Audited)
    Current Assets
      Cash and cash equivalents          $56,303,043       $ 40,288,116
      Accounts receivable, net            23,670,142         14,978,648
      Inventories                          3,099,451            462,351
      Prepaid and other current assets       132,372            106,386
      Land and construction deposit        8,533,952          8,513,284
        Total current assets              91,738,960         64,348,785

    Property and equipment, net           30,429,508         21,058,779
    Intangible assets, net                14,872,618         15,851,765
                                        $137,041,086       $101,259,329


    Current Liabilities
      Accounts payable and accrued
       expenses                           $6,911,404         $2,937,068
      Taxes payable                        5,763,146          3,362,888
      Deferred revenues                           --             26,079
        Total current liabilities         12,674,550          6,326,035

    Commitments and Contingencies                 --                 --

    Stockholders' Equity
      Preferred stock ($0.001 par value,
       5,000,000 shares authorized, none
       issued and outstanding)                    --                 --
      Common stock ($0.001 par value,
       50,000,000 shares authorized,
       16,661,423 and 16,306,184 issued
       and outstanding, respectively)         16,661             16,306
      Additional paid-in capital          40,133,948         40,105,134
      Accumulated other
       comprehensive income                5,812,108          5,566,806
      Retained earnings                   78,403,819         49,245,048
        Total stockholders' equity       124,366,536         94,933,294
                                        $137,041,086       $101,259,329

                   China Sky One Medical, Inc. and Subsidiaries
      Condensed Consolidated Statements of Operations and Comprehensive Income

                             Three Months Ended          Nine Months Ended
                                September 30,               September 30,
                             2009          2008          2009          2008
    Revenues             $43,227,171   $29,699,282  $100,242,453   $65,861,304
    Cost of Goods Sold    10,897,185     7,366,059    24,690,474    15,748,801
    Gross Profit          32,329,986    22,333,223    75,551,979    50,112,503

    Operating Expenses
      Depreciation and
       amortization          447,170       308,023     1,347,836       523,375
      Research and
       development         4,884,925     1,866,409    10,979,619     3,881,312
      Selling, general
       and administrative 10,967,649     7,596,953    26,061,465    18,140,807
        Total operating
         expenses         16,299,744     9,771,385    38,388,920    22,545,494

    Other Income
      Other (expense)           (483)           --        (1,611)           --
      Interest income
       (expense)              20,900        (1,494)       47,854      (135,136)
        Total other
         income (expense)     20,417        (1,494)       46,243      (135,136)

    Net Income Before
     Provision for
     Income Tax           16,050,659    12,560,344    37,209,302    27,431,873

    Provision for
     Income Taxes
    Current                3,591,719     2,616,909     8,050,531     5,512,860

    Net Income           $12,458,940    $9,943,435   $29,158,771   $21,919,013

    Basic Earnings
     Per Share                 $0.75         $0.64         $1.76         $1.50

    Basic Weighted
     Average Shares
     Outstanding          16,655,697    15,464,084    16,535,924    14,657,059

    Diluted Earnings
     Per Share                 $0.74         $0.60         $1.76         $1.39

    Diluted Weighted
     Average Shares
     Outstanding          16,741,745    16,492,414    16,606,576    15,745,542

      Net Income         $12,458,940    $9,943,435   $29,158,771   $21,919,013
      Foreign currency
       adjustment            121,913       441,809       245,302     3,597,598

     Income              $12,580,853   $10,385,244   $29,404,073   $25,516,611

                 China Sky One Medical, Inc. and Subsidiaries
                Condensed Consolidated Statements of Cash Flows

                                          Nine Months Ended September 30,
                                            2009                  2008
    Cash flows from operating

    Net Income                          $29,158,771           $21,919,013

    Adjustments to reconcile net
     cash provided by
     operating activities:
      Depreciation and amortization       1,752,927               523,375
      Share-based compensation expense           --                30,351

    Net change in assets and
      Accounts receivables               (8,659,683)            1,618,365
      Inventories                        (2,634,086)           (1,431,757)
      Prepaid expenses and other
       current assets                       (14,948)              (10,763)
      Accounts payable and accrued
       expenses                           3,938,248             1,589,409
      Taxes payable                       2,390,378             2,475,042
      Deferred revenues                          --               (24,504)

    Net cash provided by
     operating activities                25,931,607            26,688,531

    Cash flows from investing
      Purchase of fixed assets             (122,093)             (784,137)
      Purchase of
       subsidiary-Tianlong and Haina             --           (10,917,280)
      Purchase of construction in
       progress                          (9,926,849)                   --
      Purchase of intangible assets              --                (7,139)

    Net cash used in investing
     activities                         (10,048,942)          (11,708,556)

    Cash flows from financing
      Sale of common stock for
       cash, net of offering costs               --            23,487,963
      Proceeds from warrants
       conversion                            29,169             1,044,169

    Net cash provided by
     financing activities                    29,169            24,532,132

    Effect of exchange rate
     changes on cash                        103,091             2,245,553

    Net increase in cash and
     cash equivalents                    16,014,926            41,757,660

    Cash and cash equivalents at
     beginning of period                 40,288,117             9,190,870

    Cash and cash equivalents at
     end of period                      $56,303,043           $50,948,530

    Supplemental disclosure of
     cash flow information

    Interest paid                               $--              $135,136

    Taxes paid                           $6,569,901            $5,512,860

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-0451-53994069

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915

SOURCE China Sky One Medical, Inc.

SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
(Date:11/24/2015)... , November 24, 2015 st  Scientific Assembly ... America (RSNA) taking place in Chicago ... 1122, Hall A. --> st  Scientific Assembly and Annual ... (RSNA) taking place in Chicago on ... A. --> Molecular Dynamics will present its revolutionary whole ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology:
(Date:11/24/2015)... Church, VA (PRWEB) , ... November 24, 2015 , ... ... — 1:30 p.m. – 3:00 p.m. EST, , FDA has long ... regulations. CLIA regulations apply to performing the tests and do not meet the device ...
(Date:11/24/2015)... ... November 24, 2015 , ... The ... waive paid entry and parking fees at several of their most popular properties, ... Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The Trustees encourage ...
(Date:11/24/2015)... ... November 24, 2015 , ... In response to recent news highlighting Oxycodone ... prescription opioids in the United States grew 400 percent between 1999 and 2010, far ... involved in 37 percent of all fatal drug overdoses. (1) , While oxycodone and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, family ... a live taping of the next CURE Connections® video series on ... 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s leading provider ... pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is designed to ... The location is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic , ...
Breaking Medicine News(10 mins):